Mansoor A. Khan, PhD - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Mansoor A. Khan, PhD


Mansoor A. Khan, PhD
Director,
FDA/CDER/DPQR

Mansoor A. Khan is the director of product quality research in the Center for Drug Evaluation and Research at the US Food and Drug Administration. Prior to joining FDA, Khan was a professor of pharmaceutics and director of graduate program in the School of Pharmacy at Texas Tech University Health Sciences Center. He is a registered pharmacist, and earned his PhD in Industrial Pharmacy from the St. John's University School of Pharmacy at New York in 1992. He has published more than 135 peer-reviewed manuscripts, four texts including Pharmaceutical and Clinical Calculations, five book chapters, and given more than 125 presentations in various meetings. Khan advised 10 PhD students in pharmaceutics.

Khan's research focus is primarily in the area of quality by design and process analytical technologies, controlled drug delivery of challenging molecules, oral delivery of macromolecules, and nanoparticles. He is the chair-elect of Pharmaceutics and Drug Delivery section of the American Association of Pharmaceutical Scientists (AAPS), and has been recognized as an AAPS fellow. He serves on the editorial board of Pharmaceutical Technology, the Journal of Clinical Research and Regulatory Affairs, and the journal Critical Reviews in Therapeutic Drug Carrier Systems.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
29%
Oversee medical treatment of patients in the US.
10%
Provide treatment for patients globally.
6%
All of the above.
42%
No government involvement in patient treatment or drug development.
13%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?

Click here